Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $40.60

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has received a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $40.60.

A number of equities analysts have weighed in on DAWN shares. Piper Sandler reiterated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Finally, The Goldman Sachs Group reduced their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th.

Insider Activity at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the completion of the transaction, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Charles N. York II sold 2,666 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $40,656.50. Following the completion of the transaction, the chief financial officer now owns 277,754 shares in the company, valued at approximately $4,235,748.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. Insiders sold a total of 45,781 shares of company stock worth $722,960 in the last 90 days. Corporate insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System boosted its holdings in Day One Biopharmaceuticals by 1.4% in the 4th quarter. California State Teachers Retirement System now owns 52,923 shares of the company’s stock worth $773,000 after buying an additional 731 shares during the last quarter. Laurion Capital Management LP boosted its holdings in Day One Biopharmaceuticals by 5.4% in the 4th quarter. Laurion Capital Management LP now owns 15,000 shares of the company’s stock worth $323,000 after buying an additional 763 shares during the last quarter. Arizona State Retirement System boosted its holdings in Day One Biopharmaceuticals by 8.8% in the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock worth $152,000 after buying an additional 995 shares during the last quarter. Quintet Private Bank Europe S.A. boosted its holdings in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after buying an additional 1,000 shares during the last quarter. Finally, Parkwood LLC boosted its holdings in Day One Biopharmaceuticals by 5.3% in the 1st quarter. Parkwood LLC now owns 20,381 shares of the company’s stock worth $272,000 after buying an additional 1,028 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $14.96 on Wednesday. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -6.29 and a beta of -1.48. The business has a fifty day moving average of $15.22 and a 200 day moving average of $13.70. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, equities research analysts expect that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.